Most recently, Mr. Szekeres served as deputy general counsel, chief M&A counsel and assistant secretary at Life Technologies Corp., where he led more than fifty transactions valued at more than $30 billion, including the merger of Applied Biosystems and Invitrogen in 2008 and the acquisition of Life by Thermo Fisher Scientific in 2013. Mr. Szekeres was responsible for all legal functions in the areas of corporate transactions, corporate governance, SEC reporting and compliance, and was responsible for expanding Life's diagnostics business with several strategic acquisitions.
"We are very pleased to welcome David to our Regulus team at such an exciting time for the company," said Kleanthis G. Xanthopoulos, Ph.D., president and chief executive officer of Regulus. "David's involvement with transformative strategic transactions and overall operational experience at Life will add both depth and strategic capabilities to our well rounded team as we continue to build Regulus into a top-tier biopharmaceutical company. We are dedicated to RNA therapeutics and to leading the discovery and development of a new and major class of medicines targeting microRNAs."